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Capsaicin is known to interfere with tight junctions (TJ) of epithelial cells and therefore to enhance 
paracellular permeability of poorly absorbable drugs. However, due to its low water solubility, pungency 
and cytotoxicity its pharmacological use is limited. In this study, we investigated the effect of capsaicin 
derivatives of synthetic ( 10*hydroxy*N*(4*hydroxy*3*methoxybenzyl)decanamide, etc.) and natural 
(olvanil and dihydrocapsicin) origin on MDCK*C7 cells. Impedance spectroscopy was used to determine 
the transepithelial electrical resistance and the capacitance. Permeability assays with FITC*dextran were 
carried out to evaluate the impact on cell permeability. The results show that lipophilicity could play an 
important role for the interference with TJ and that the mechanism is independent from the ion channel 
TRPV 1 and hence, on the flux of calcium into the cells. In summary, we synthesized four derivatives of 
capsaicin of lower lipophilicity and compared their properties with other well*known vanilloids. We show 
that these compounds are able to enhance the permeability of a hydrophilic macromolecule, by opening 
the TJ for a shorter time than capsaicin. This behavior is dependent on the lipophilicity of the molecule. 
Understanding of these phenomena may lead to better control of administration of therapeutic molecules. 
 MDCK cells, permeability, drug design, structure*activity relationship, solubility 
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Capsaicin is known for its pungent taste and occurs in Nature as a constituent of chili peppers. It 
stimulates the TRPV*1 receptor, a relatively non*selective calcium channel, which is responsible for the 
sensation of heat 
1
. Capsaicin is known to have versatile therapeutic effects like the treatment of chronic 
pain via the desensitization of afferent sensory neurons 
2
. Other applications are the control of body 
temperature or as anti*obesity drug 
3, 4
. More recently it has been discovered that capsaicin has a 
profound reversible opening effect on cellular tight junctions (TJ) 
5
. This rigid cell connecting network of 
transmembrane proteins which is linked to the actin skeleton can be found in epithelial and endothelial 
tissues 
6
. It serves as a protection mechanism to control the permeation of unknown compounds. 
Especially hydrophilic macromolecular drugs (e.g., proteins, polysaccharide, polynucleotides, etc.) are 
often unable to cross this barrier 
7
. The property to reversibly open TJ makes capsaicin a potential 
permeability enhancer for drugs with a poor bioavailability 
8*10
. However, the use of capsaicin also entails 
several drawbacks associated to its strong pungency and known cytotoxicity 
11
. The application of high 
doses is not tolerable, especially in case of sensitive administration routes like the nasal or oral mucosae. 
Furthermore, its lipophilic character causes solubility difficulties when handling the compound in aqueous 
environments 
12
, which complicates a precise administration. Our previous studies in MDCK*C7 cells 
monolayers have shown that capsaicin is able to open reversible TJ for a time span of more than 10 h 
even at lower concentrations (≤ 500 mM) 
10
. For a specific uptake of the delivered drug an immediate cell 
response and a very short time of opening would be advantageous to reduce the permeation of undesired 
substances. Based in this, we reasoned that it would be appropriate to modify the structure of capsaicin to 
improve its properties for the desired application. In the past, various capsaicin analogues have been 
synthesized mainly with the goal to find new agonists and antagonists 
13*15
. Later, resiniferatoxin 
16
, an 
agonist which is 3 to 4 orders of magnitude more potent than capsaicin, and capsazepine 
17
, the first 
known antagonist, have been discovered. Also the structure*function relationship between different 
analogues and the TRPV1 activation has been studied 
18*21
. It has been found that different analogues 
induce varying profiles of calcium release inside cells 
22
 and furthermore that too high hydrophilicity or 
hydrophobicity reduces the pungency of a compound 
15, 23
. This can be explained by different permeability 
behaviors of compounds of different polarity through the cell membrane 
23
. TRPV 1 receptors are also 
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expressed in the endoplasmatic reticulum and can release calcium ions from internal storages 
18, 24
. In 
light of this, it has been hypothesized that different permeability behaviors influence also the release 
profile of intracellular calcium ions 
25
, which could in turn also affect other responses of the cell. Our goal 
was to establish a comparison between molecular features of capsaicin derivatives of synthetic and 
natural origin, and their biological activities in mammalian cells. In particular, we addressed the influence 
of these compounds on the paracellular transport of a model hydrophilic macromolecule (FITC*dextran). 
We aimed to shorten the duration of the TJ opening effect in comparison to capsaicin, thus facilitating a 
narrow time window of enhanced cell permeability. To this end, we synthesized four capsaicin analogues 
(!"#!$#!%#&') which have a low lipophilicity and also included capsaicin &!, vanillin !, dihydrocapsaicin 
&& nonivamide &" and olvanil &$ in the study(Figure 1). We used the MDCK*C7 cell line as it is known to 
form a barrier of high integrity 
26
. Impedance spectroscopy measurements, using a CellZscope device 
27
 
for online measurements, were performed to determine the transepithelial electrical resistance (TEER) 
and the capacitance (CCL). To investigate permeation of a model macromolecule (FITC*dextran 4000 Da), 
cell permeability assays using were carried out. Furthermore, the influx of calcium into the cells was 
investigated. Our study shows that different derivatives of capsaicin modify the effect of reversible TJ 
opening and molecular transport.  
()
	
*	()
	: 
All the chemicals were purchased from Spectrochem, Avra, Merck and Sigma*Aldrich Chemical 
Companies and were of the highest purity. Capsaicin, dihydrocapsaicin, nonivamide and olvanil were 
purchased from Sigma*Aldrich (Steinheim, Germany). The protocol of synthesis of the compounds !", !$, 
!% and &' is described in the Supporting Information.

MDCK*C7 cell line was cultured using MEM supplemented with 10% of fetal bovine serum, 1% of L*
glutamine (200 mM) and 1% of penicillin*streptomycin (10000 units penicillin, 10000 units streptomycin in 
0.9% NaCl) in 75 cm² flasks. The cultures were kept in an incubator set to 5% of CO2 and 37°C (Sanyo 
MCO*19AIC, Panasonic Biomedical Sales Europe BV., AZ Etten Leur, Netherlands). The passages 41 to 
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47 were used for all of the experiments. Those were carried out as independent triplicates on different 
days. After forming a confluent monolayer the cells were rinsed with 10 ml of PBS and trypsinized with 10 
ml of trypsin buffer (0.05% trypsin EDTA). The trypsin buffer was diluted after detachment with 10 ml of 
cell culture medium. The cells were centrifuged at 1000 rpm for 5 min in a falcon tube (Rotina 420 R, 
Hettich GmbH, Tuttlingen, Germany). Supernatant was removed and the cell pellet was resuspended in 1 
ml of cell culture medium. For counting 10 Kl of cell suspension was diluted with 90 Kl of trypan blue and 
transferred to an improved Neubauer chamber. Afterwards the cells were used for experiments. For 
subculture the cells were split in the ratio of 1:10. 
(	
		
The CellZscope® (nanoAnalytics, Münster, Germany), an automated impedance spectrometer, was used 
to determine the TEER and the capacitance CCL of a cell monolayer. Into the basolateral chamber of 
transwell Permeable Supports (12 mm Transwell with a 0.4 Km pore polycarbonate membrane insert; 
Corning Inc., New York, USA) approximately 1.5 ml of cell culture medium was filled. The apical 
compartment was loaded with 500 Kl of cell suspension for seeding. A density of ≈25000 cells per well 
was chosen. The cells were allowed to form a monolayer for 4 days. One day prior to the experiment, 
every well was filled with 1.5 ml of supplement free medium. The cell culture medium of the supports was 
also replaced in the apical compartment by serum free medium. The membranes were transferred into the 
device and allowed to acclimate in the incubator and to reach a constant resistance of at least ≈5000 
P*cm². By replacing 250 Kl of the medium in the apical chamber by the sample dissolved in medium with 
the double of the desired concentration the experiment was started. The resistance and capacitance was 
continuously measured for 24 hours. The normalized TEER and capacitance was calculated according to 
the following equation (Eq. 1): 
 (1) 
+			
For the experiment cells were seeded on transwells with a density of 25000 cells/well. As transport 
medium modified MEM without phenol red supplemented with 1% L*glutamine, 1% of 
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penicillin/streptomycin and 10% FCS was used. As described previously for the TEER experiments the 
same volumes of medium were used to fill the compartments. The cells were cultured for 4 days to 
develop confluent monolayers. Afterwards the medium was exchanged with serum free transport cell 
growth medium and allowed to acclimate overnight. After acclimation TEER was determined for the 
transwells. Only filters with an electrical resistance of more than 5000 P*cm² were used for further 
experiments. To start the experiment half of the medium of the apical chamber was replaced by the same 
medium containing a twice as high sample concentration compared to the desired value and 37.5 Kl of 50 
mg/ml solution of fluorescein isothiocyanate*dextran (FITC*dextran, molecular weight 4000 Da, 
FITC:Glucose 1:250, Sigma*Aldrich GmbH, Steinheim, Germany). Aliquots of 100 Kl of the medium in the 
basolateral chamber were collected after 1, 3, 5, 7, 9 and 24 hours and replaced with new medium. The 
aliquots were transferred into a 96*well plate (UV star black f*bottom, chimney well, K clear, Greiner Bio*
one GmbH, Frickenhausen, Germany) and fluorescence (λex = 485 nm, λem = 520 nm) was measured in a 
in a microplate reader (Safire, Tecan AG, Salzburg, Austria).  Papp was calculated using the following 
equation (Eq. 2): 
 (2) 
The experiment was carried out as four independent replicates with three technical replicates each. 
	)	
Cells were seeded to form a confluent monolayer in an 8*well microscopy slide (K*Slide 8 Well ibiTreat, 
ibidi GmbH, Munich, Germany) and allowed to attach to the surface overnight. After a washing step with 
supplement free medium each well was filled with 100 Kl of medium containing Fluo*4 (1Kl of 5 mM stock 
solution in 1 ml). The cells were incubated for 20 minutes. To remove the excess of dye the cells were 
rinsed with HEPES*buffered Ringer’s solution (10 mM HEPES, 5 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 
5 mM KCl, 140 mM NaCl). Afterwards, 200 Kl of HEPES buffer was filled in every well and the slide was 
immediately used for the experiment. Microscopy was performed using SIFM using an inverted 
fluorescence microscope (AxioObserver.Z1, Zeiss, Jena, Germany) equipped with a structured 
illumination module (ApoTome, Jena, Germany). A time lapse measurement was started (~0.88 
frames/second). After recording about 20 frames 100 Kl of sample containing 375 KM of test substance 
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was added using a pipette to reach an overall concentration of 125 KM. The time lapse was continued for 
around 5 minutes. For further analysis the images were processed with ImageJ. The images were 
normalized with a background subtraction using a rolling ball algorithm (ball radius = 500 pixels). 
Afterwards the brightness was adjusted. The overall brightness of the image was plotted over time and the 
brightness value before the addition was defined as zero. 
(	,+	
Theoretical Log P values have been calculated using ChemBioDraw Ultra version 14.0.0.117 (Perkin 
Elmer Inc., Waltham, USA). 
				
Statistical analysis of biological experiments was performed using Prism version 6.0c (GraphPad Software 
Inc., La Jolla, USA). All experiments have been statistically analyzed using non*parametric tests. For 
unpaired tests the Kruskal*Wallis test was applied and for paired tests the Friedman test was used. All 
biological experiments were conducted at least in triplicate. 
-
In this study we have investigated, in addition well*known capsaicin derivatives, the properties of four new 
derivatives with different hydrophilic groups in the aliphatic chain. Our reasoning for this was to gain a 
deeper understanding of the role of the length and molecular features of the aliphatic chain of vanilloids on 
their biological activity on epithelial cells. In particular we were interested in the paracellular permeability 
across monolayers of MDCK*C7 cells.  
(		,+	
To estimate lipophilicity of the derivatives theoretical Log P values were calculated. The theoretical Log P 
values are shown in Figure 1. The lowest Log P values were found for the synthesized compounds !"
(Log P: 1.2) and !% (Log P: 0.73). Then vanillin ! had the next higher Log P value (Log P: 1.27). The other 
two synthesized compounds !$ (Log P: 2.87) and &' (Log P: 2.4) followed. Nonivamide &" (Log P: 3.65), 
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capsaicin &! (Log P: 3.66) and dihydrocapsaicin && (Log P: 3.98) were the compounds with the next 
higher Log P values. Olvanil &$ (Log P: 7.09) had the highest value of all compounds. 
)
To find out the influence of the investigated compounds on cell viability we applied different concentrations 
on a monolayer of cells seeded on filter membranes. The cell viability was evaluated by continuous 
capacitance (CCL) measurements over 24 hours (Figure 2) using the CellZscope® instrument. The plots 
show the normalized CCL profiles over time for all the tested compounds at varying concentrations. 
Inspection of the plots shows that the synthesized compounds !", !$, !% and &' when applied at doses of 
250 and 500 M had no pronounced effect on CCL. However, compound !% when applied at 750 KM 
increased slightly the response after 5 h. Vanillin! did not induce any observable change of CCL even at 
the highest dose. Olvanil &$ at concentrations 250 and 500 KM did not had any effect. At a concentration 
of 750 KM though, it exerted a noticeable effect which started at about 9 h and persisted until the time of 
the analysis elapsed. This was reflected by the progressive increase of the standard deviation of the CCL 
values and also by a slight increase in CCL seen after 20 h. In turn, dihydrocapsaicin && had a very 
pronounced effect. At a concentration of 250 KM the response decreased slightly in the time course of the 
measurement until about 12 hours down to a value of 0.9. Beyond this time point it slightly recovered but 
did not reach its initial value. At a concentration of 500 KM, a strong sudden decrease can be appreciated 
in the beginning of the assay. After ~5 h the CCL increased rapidly to a value of 5.0 with no further change 
beyond this point. At a concentration of 750 KM, a sudden increase occurred 1 h after the beginning of the 
measurement and reached a steady value of ~10.0. For nonivamide &" there was a dose*dependent 
decrease of the CCL traces.  At a concentration of 250 KM this effect was comparable to the behavior after 
treatment with dihydrocapsaicin && at similar concentration. By contrast, at the higher concentrations the 
decrease in capacitance became more pronounced and also the endpoint CCL values were lower than the 
initial ones. Also the behavior of capsaicin &! at 500 M was similar to nonivamide &". 
(
((-
The changes in TEER behavior were also studied concomitant to the CCL measurements. In Figure 3 the 
normalized TEER is shown over a time span of 24 hours. The synthesized compounds (!"#!$#!%and&'. 
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showed a comparable effect on the normalized TEER behavior. Almost immediately after beginning of the 
measurement the TEER started to decrease and reached its minimum value after about two hours. The 
values reached were between 0.8 and 0.6 and compound !$ had the most prominent effect followed by 
compound &'. The minima in TEER was followed by an increase to a value of ~0.90 which was reached 
after about 3 h for all the synthesized substances. Beyond this point the values continued increasing 
moderately over time. During this process the initial values were exceeded slightly. A dose dependency 
was not observable for any of these compounds. In case of vanillin ! a similar behavior was visible with 
the difference that the decrease was far less prominent compared to the compounds !", !$, !% and &'. 
The minimum TEER value for vanillin ! was about ~0.95 and also in this case no dose dependency was 
observable. For olvanil &$ there was a minor increase of the TEER visible starting from 4 h. After 9 h at a 
concentration of 750 KM a monotonic decrease of the TEER occurred that continued until the end of the 
experiment. Dihydrocapsaicin && applied at a concentration of 250 KM, led to a sudden increase of the 
TEER at the beginning of the experiment, followed by a decrease that described 3 waves, with minima at 
~1 (TEER: ~ 0.75), ~4 (TEER: ~ 0.6) and ~10 hours (TEER: ~ 0.5). Afterwards, the TEER increased and 
exceeded the initial value at about 1.5*fold. At higher concentrations dihydrocapsaicin &&caused a total 
loss of the TEER. Nonivamide &" at a concentration of 250 KM had a comparable effect to the one 
observed for dihydrocapsaicin &&. At 500 KM the overall effect was more pronounced while at a 
concentration of 750 KM the TEER did not recover fully. Capsaicin &! at a concentration of 500 KM 
showed a similar effect as that of nonivamide &" at the same concentration.  
+	
We conducted permeability assays across cell monolayers by applying the vanilloid compounds at a 
concentration of 500 KM. FITC*labeled dextran served as a probe to quantify permeability of a model 
macromolecule. Values of the amount of FITC*dextran were calculated after 9 and 24 h (Figure 4a) along 
with the relative permeability coefficient calculated at the time point of 9 h (Figure 4b). In both figures the 
compounds are aligned according with ascending Log P values. For the cumulative transport after 9 h 
(Figure 4a) it is worth noticing that all the investigated substances enhanced the amount of permeated 
probe with respect to the control. However, out of the synthesized compounds only !$ was to reach 
statistical significance (P ≤ 0.001). Also capsaicin &! (P ≤ 0.0001), nonivamide &" (P ≤ 0.0001), and
Page 8 of 69Journal of Pharmaceutical Sciences
olvanil &$(P ≤ 0.01) increased the permeability of FITC*dextran in a statistically significant manner. After 
24 h a significant enhancement was not visible anymore for compound !$ while the other substances did 
maintain this behavior. Dihydrocapsaicin && enhanced the permeability very drastically at both of the time 
points investigated (P ≤ 0.0001). Regarding the relative permeability coefficients estimated after 9 h 
(Figure 4b) notice that the compounds !"#!$#!%and&' enhanced the permeability in a range between 
1.2 and 1.6 fold in comparison to the control. Especially compound !$ showed a statistically significant 
permeability increasing effect (P ≤ 0.01). Also in case of vanillin ! a slight but not statistically significant 
increase (1.2*fold) after 9 h was observable. Capsaicin &! and nonivamide &" showed a comparable 
behavior. Both compounds increased significantly (capsaicin &!: P ≤ 0.01, Nonivamide &": P ≤ 0.001) the 
permeability by about 1.6*fold in comparison to the control. Olvanil &$ increased the permeability 
significantly after 9 h to around 1.9 (P ≤ 0.0001). In case of dihydrocapsaicin && the permeability 
increased dramatically to a value of 350*fold (P ≤ 0.0001). The inset in Figure 4b shows the dependency 
of the relative permeability on the Log P values of the investigated compounds. Notice that there is a 
strong linear correlation (R² = 0.87) between the permeability enhancement and the lipophilicity of the 
compounds. 
In Figure 5 are plotted the time traces of relative cumulated permeated amount of probe along with the 
normalized TEER results for four representative compounds. A general consistent trend is appreciated 
between the increase in the amount of permeated probe and the decrease of TEER and vice versa. In 
case of nonivamide &" the initial increase in TEER showed a reduced permeability at the beginning of the 
experiment. Also for compound !$ the relative permeability is reduced after 24 hours. The TEER crosses 
the initial value at around 6 hours. Increases in permeability were seen for nonivamide &" especially 
between 5 and 10 h when the TEER reached its minimum value. Also for compound !$ a peak of 
permeability centered at ~3 h was accompanied by the drop in TEER after ~2 h. In case of vanillin ! the 
permeability remained close to the initial value consistent with a minor change in TEER. By contrast with 
nonivamide &" and compound !$, olvanil &$ did enhance dramatically the permeability of the probe 
without any major effect on the TEER. Notice that the enhancement of permeability started at the same 
time as the minor TEER increase at around 4 hours. 
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The microscopy study in Figure 6 describes the calcium (Ca
2+
) influx behavior of MDCK*C7 after the 
stimulation with the synthesized compounds !", !$, !%, and &', and capsaicin &! (video file available as 
Supporting Information). To investigate this behavior the cells were loaded with a dye (Fluo*4) which starts 
to fluoresce after complexation with calcium. The figure shows the cell monolayer before and after the 
stimulation with the different substances. The images for the stimulated cells always show the maximal 
response observed. The upper panels correspond the micrographs for the control treatments, namely 
HEPES buffer (negative control), ionomycin (positive control), and capsaicin &! (reference compound). 
For the negative control no change of fluorescence was noticed. As positive control we applied ionomycin, 
known to transport calcium across cellular membranes, and it showed a strong increase in fluorescence 
after the end of the assay (24 s). By contrast, capsaicin and the investigated substances did not show any 
increase in fluorescence after the stimulation of the cells when at a concentration of 125 KM. On the panel 
shown at the right side of the micrographs, the evolution of the fluorescence intensity during the course of 
the experiment is plotted. We also carried out a PCR assay to analyze the presence of the TRPV 1 
receptor in the investigated cell line. There was no evidence of its expression under the conditions applied 
(see Supporting Information). 

In this study, we addressed the effect of various capsaicin derivatives from natural and synthetic origin on 
the drug permeability of MDCK*C7 cell monolayers. To this end, biophysical combined with biological 
methods have been used. We have chosen the MDCK*C7 cell line because it is a commonly used 	
 
model of an epithelial barrier and for drug transport. Also it is suitable for impedance spectroscopy studies 
on cell monolayers 
8, 10, 28
.  It has been argued that the biological effects of capsaicin on epithelial cells are 
general, as previously shown for Caco*2 and MDCK cells 
8
. 
We evaluated the cytotoxic response of the studied compounds from the capacitance values (CCL) 
determined by impedance spectroscopy, as documented elswhere 
29
. Also, the CCL parameter is known to 
be a probe of cell adhesion processes on substrates and changes of cell shape 
30
. In a previous study, we 
used this method along with a conventional metabolic competence assay (MTT), as reference, to assess 
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the cytotoxicity of capsaicin, and found that the results from both methods were comparable 
10
. The study 
shows that the newly synthesized compounds !", !$, !% and &' did not exhibit any cytotoxic properties at 
any of the tested concentrations. Also vanillin ! showed a similar behavior. In case of olvanil &$ a change 
in the morphology of the cell monolayer was observable at a concentration of 750 KM with an onset time 
of 9 h. It is not clear in this case if the cells were harmed as the increase in capacitance is not pronounced 
enough. Furthermore, the TEER values also indicated that there was no complete disruption of the 
integrity of the cell monolayer which suggests that it was still intact. For nonivamide &" and capsaicin &! a 
slight dose*dependent decrease in capacitance was visible. The slight decrease of capacitance could be a 
result of an alteration of the physical and/or morphological properties 
30
. This modification might be directly 
connected with the pronounced decrease in TEER induced by these compounds (Figure 2). These results 
are in general agreement with our own parallel studies using Caco*2 and TR146 epithelial cells 
31, 32
. Also 
dihydrocapsaicin && showed a comparable decrease in capacitance at a sub lethal concentration of 
250 KM, while higher concentrations lead to detachment of the dead cells as evidenced by the 
pronounced increase of capacitance. 
The TEER results for capsaicin &! are in close agreement with our previous studies where we 
investigated the profiles for a wider range of concentrations 
10
. For all synthesized compounds an initial 
decrease of TJ integrity was observed, but not for nonivamide &", capsaicin &! or dihydrocapsaicin &&. 
Also a dose dependency of the observed effects was not visible for the synthesized compounds as it was 
for the other derivatives. Olvanil &$# in contrast to all the other tested substances, initiated a decrease of 
TEER starting at ~ 9 h. This cannot be attributed to cytotoxicity as the capacitance remained unaffected. 
The long response time observed may be related to the high lipophilicity of olvanil &$ (i.e., Log P = 7.09). 
A longer retention in the cell membrane could explain the delayed onset of response, as previously 
suggested 
23
. All the compounds showing a reversible decrease of TEER recovered to a higher value than 
the initial. This also suggests that the cell morphology could be affected as already indicated for the 
capacitance results. 
Permeability studies support the findings of the TEER measurements. Notice that after 9 h there was an 
increase of Papp visible for all the studied compounds which induced a decrease of TEER. However, for 
compounds !", !% and &' this effect was not statistically significant, by contrast with compound !$ which 
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showed a significant Papp increase. Also, the cumulated transported amount of probe increased at time 
points where TEER was reduced (Figure 5). Olvanil &$ was an exception as Papp increased even without a 
major TEER decrease at comparable concentrations. After 24 hours all compounds which did not show a 
permanent TEER decreasing effect also did not increase permeability values. It can be hypothesized that 
a possible morphological change after initial decrease of the TEER even slowed down permeability as 
TEER exceeds the initial value. This would explain why the cumulated transported amount of the probe 
approaches again the control value for compound !$ (Figure 5). Olvanil &$ shows a very high permeability 
after 24 hours which cannot be explained within the present study as TEER values do not show a 
decrease. Nevertheless a cellular response at the time point of 9 hours was evident in case of 
capacitance and TEER. This time region also marks the change in permeability profile (Figure 4). 
Enhancement of calcium uptake was observed neither for capsaicin nor for the newly synthesized 
compounds (Figure 6). This allows the conclusion that the mechanism of permeability enhancement is not 
dependent on the TRPV 1 receptor as it is furthermore not expressed in the investigated cell line 
(supporting information). In previous studies it has been shown that the activation of cofilin and the 
reduction of tight junction protein occludin is involved in the reversible effect of tight junction opening 
8, 33
. 
The results suggest that lipophilicity could not only be important for the pungency of the 
capsaicionoids 
15, 23
 but also for the effect on paracellular permeability even though it can be assumed that 
the TRPV1 is not involved in the mechanism. We have gained evidence that the permeability coefficient 
increases with increasing Log P value for the non*cytotoxic compounds (Figure 4). As already stated in 
literature the presence of an optimum of lipophilicity for crossing the cell membrane 
23
 could play an 
important role for the effect on permeability. Experiments show that derivatives with a Log P value below 3 
are not able to have a pronounced effect on TEER. A possible explanation could be that these 
compounds are not able to cross the cell membrane as effectively as compounds with a higher lipophilicity 
which reduces an interaction with intracellular structures. This could also explain the absence of a dose*
dependent response for these compounds as only the area of the cell membrane could be involved which 
could be saturated already at the lowest amount investigated. Capsaicin &!, nonivamide &" and 
dihydrocapsaicin && show very pronounced effects on TEER and permeability as they are in the optimal 
range of lipophilicity. This has been shown for the pungency intensity of these compounds 
23
. Olvanil &$, a 
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compound with a very high Log P value, shows a very belated response. This could be explained by the 
long residence time of the compound inside the lipid bilayer of the membrane 
23
. However, for this 
derivative an enhancement of permeability also at time points where TEER was not strongly affected was 
observed. Nevertheless it correlates with the general trend that a higher Log P value of the vanilloid 
increases the permeability of hydrophilic macromolecules. Recent studies have shown that the TRPV*4 
receptor can influence TJ integrity via claudin*2 downregulation induced by hyperosmotic effects 
34
. The 
calcium influx experiments did not show a positive result even though TRPV*4 was expressed in the 
investigated cell line. Whether vanilloid compounds addressed in this study have a different effect on the 
TRPV*4 channel remains to be investigated. 

In summary, vanilloids which are less lipophilic than capsaicin &! have been synthesized and compared 
with commercially available compounds aiming to improve some of the limitations of capsaicin and 
expand its pharmacological use. The new derivatives (!", !$, !% and &') are all able to open reversibly TJ 
for a short period of time upon administration which results in a short enhancement of permeability of 
FITC*dextran. This could allow a more precise enhancement of the absorption of a co*administered drug. 
Especially compound !$ seems to be a potential candidate for further studies as it increases the 
permeability significantly, shows no cytotoxicity and induces a very narrow profile of reversible tight 
junction opening. We venture to suggest that the observed biological activities of this compound stem on 
the molecular features, namely the length of the aliphatic chain along with the presence of a terminal 
hydroxyl group. We show for the first time that there is a consistent trend between the lipophilicity of 
vanilloid compounds and their effect on transport of a hydrophilic macromolecule. Less lipophilic 
compounds showed a rapid effect on TJ after administration and this is accompanied by a rapid increase 
of drug permeability. In addition, we show that the TRPV 1 receptor is not necessarily required to induce 
this effect in MDCK*C7 cells. The mechanism of this process has to be further evaluated and elucidated at 
the molecular level. We trust that the results of this study contribute to identify potential new non*toxic 
vanilloids which could be used as drug permeability enhancers. 

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
3!4 Vanilloids which have been used for this study. The thereoretical Log P values were estimated. 
3 &4 Impedance spectroscopy measurements for determination of capacitance: Normalized 
capacitance in relation to the control for increasing concentrations over time. Color code: 250 KM: black; 
500 KM: green; 750 KM: red. The plot shows mean values ± s.d. (n=3). 
3 "4 Impedance spectroscopy measurements for determination of TEER: Normalized TEER in 
relation to the control for increasing concentrations over time. Color code: 250 KM: black; 500 KM: green; 
750 KM: red. The plot shows mean values ± s.d. (n=3). 
3$4 Permeability assay with MDCK*C7 cells using FITC*dextran (MW= 4000 Da). Derivatives were 
investigated with a concentration of 500 KM. Cumulated permeated amounts of probe after 9 and 24 h (a), 
relative permeability coefficient in relation to the control (Papp) derived from the slopes of the transport 
curves after 9 hours (b). Compounds are aligned in increasing Log P. Inset shows the dependency of 
Log P and Papp of the investigated compounds. Mean values ± s.d., Statistical test: Kruskal*Wallis test 
(n=4, ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
3 54 Cumulative amount of dextran permeated plotted together with TEER behavior over time for 
representative derivatives at a concentration of 500 KM. Mean values ± s.d.. 
(TEER: n=3, Permeability: n=4). 
364 Calcium (Ca
2+
) influx measurements using Fluo*4 to quantify the amount of calcium fluxed into 
the cells. Image shows representative measurements. The samples were investigated at a concentration 
of 125 KM. Stimulated images show the maximum response of the cells. The fluorescence over time 
course of the experiment is plotted (Scale bar = 200 KM). 
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The synthesis of the capsaicin derivatives was commenced starting from vanillin $. Thus, selective 
protection of the phenolic hydroxyl with a *butyldimethylsilyl (TBS) group resulted in aldehyde  which 
upon reaction with hydroxylamine hydrochloride provided the corresponding oxime  
1
 in 85% yield. Pd/C 
mediated hydrogenation of   under hydrogen atmosphere gave the key intermediate amine # (Scheme 
1).  
 
$*Synthesis of vanillin derived amine#. 
The aliphatic side chain precursors for the coupling reaction were synthesized from hexan 1,6*diol ) and 
decan 1,10*diol +. Selective mono protection of the hydroxyl in ) and +with TBSCl provided the alcohols 
, and - in good yield. Oxidation of the primary alcohol in , and - with pyridiniumdichromate (PDC) lead to 
the formation of carboxylic acids . and $/(Scheme 2). 
 
. Synthesis of carboxylic acids . and $/. 
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EDCI (1*(3*dimethylaminopropyl*3*ethylcarbodiimide hydrochloride) mediated coupling reaction of #with 
carboxylic acids.and$/furnished the corresponding amide derivatives $$ and $. Deprotection of both 
the TBS groups in $$ and $ with TBAF in THF gave the capsaicin derivatives $  and $# in good yield 
(Scheme 3). 

 . Synthesis of capsaicin derivatives $  and $#.
On the other hand, selective deprotection of aliphatic OTBS group in $$ and $ with CeCl3.7H2O in 
refluxingacetonitrile provided the corresponding primary alcohols$)and$+
2
. Oxidation of the alcohol 
with pyridiniumdichromate provided the aldehydes$,and$-. Deprotection of phenolic TBS group in $, 
and $- with TBAF gave the corresponding capsaicin derivatives$.and/(Scheme 4).

#. Synthesis of capsaicin derivatives $.and/. 
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The reactions were carried out under an inert atmosphere and monitored by thin*layer chromatography 
(TLC) using silica gel GF254 plates with detection by phosphomolybdic acid (PMA) stain and by ultra violet 
(UV) detection unless otherwise mentioned. Ethanol, THF, pyridine, methanol, acetonitrile and CH2Cl2 
used in the reactions were distilled from dehydrating agents prior to use. Silica gel (100*200) was used for 
column chromatography. 
1
H, 
13
C spectra were recorded with Bruker 400 MHz or 500 MHz spectrometers 
in CDCl3. 
1
H NMR chemical shifts are reported in ppm (δ) with TMS as internal standard (δ = 0.00 ppm); 
13
C NMR data are reported in chemical shifts with solvent reference (CDCl3, δ = 77.00 ppm). IR spectra 
were recorded with a JASCO FT/IR*5300 spectrometer. High*resolution mass spectra were recorded with 
a Bruker maXis ESI*TOF spectrometer. 
#0012"2 "13	02: 
To a stirred solution of compound $ (5 g, 32.89 mmol) in dry dichloromethane (50 mL) was added 
imidazole (3.13 g, 46.05 mmol) and TBDMSCl (5.42 g, 36.17 mmol) at 0 
o
C, slowly warmed to room 
temperature, stirring was continued  for 12 h at room temperature. After completion of the reaction, 
quenched with saturated ammonium chloride solution, mixture was diluted with CH2Cl2 (3x100m L), the 
organic layer was separated, finally washed with brine and dried over anhydrous sodium sulphate, filter, 
evaporation under reduced pressure provides the crude, which was purified by silica*gel column 
chromatography using hexane/ethyl acetate as eluents gave the compound  in 80% (7 g) yield. = 0.66 
in 20% EtOAc/Hexane. 
$
%&0#//%34 2: δ 9.79 (s, 1H), 7.30*7.36 (m, 2H), 6.92 (d,  = 2.0 Hz, 1H), 3.82 (s, 3H), 0.95 
(s, 9H), 0.14 (s, 6H) ppm. 
$ 
&0$//%34 2: δ 190.8, 151.5, 151.2, 130.9, 126.1, 120.6, 110.0, 
55.3, 25.5, 18.4, *4.6 ppm. 
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#0012"2 "13	"0 2:
To a stirred solution of compound (6 g,0.02 mmol) in dry pyridine (60 mL) was added hydroxyl amine 
hydrochloride (1.88 g, 0.028 mmol) at rt and stirring was continued for 12 h, after completion of the 
reaction pyridine was removed under reduced pressure, the obtained crude product was dissolved in 
chloroform 60 mL, washed with water, the aqueous layer was washed with chloroform (2x60 mL), the 
combined organic layer was washed with brine, dried over anhydrous sodium sulphate, filter and 
evaporation using rotary evaporator provided the crude product which was purified by using silica*gel 
column chromatography over hexane/ethyl acetate gave the compound   in 85% yield (5.5 g). = 0.55 in 
30% EtOAc/Hexane.   
$
%&0#//%34 2: δ 9.68 (bs, 1H), 8.13 (s, 1H), 7.23 (d,  = 2.0 Hz, 1H), 6.97 (dd,  = 1.6 Hz,  
= 8.0 Hz, 1H), 6.85 (d,  = 8.0 Hz, 1H), 3.83 (s, 3H), 1.02 (s, 9H), 0.19 (s, 6H) ppm. 
$ 
&0$//%34
 2: δ 151.3, 150.4, 147.1, 125.6, 121.6, 120.8, 109.1, 55.4, 25.7, 18.5, *4.5 ppm.
0#0012"2 "
2		0#2:
To a stirred solution of compound   (5.5 g, 19.57 mmol) in methanol was added Pd/C (400 mg) then 
stirring was continued in presence H2 atmosphere for 5 h at rt. After completion of the reaction Pd/C was 
filtered off using celite 545 using methanol, the filtrate was evaporated under reduced pressure followed 
by column chromatography over methanol/chloroform gave the compound # in 90% yield (4.7 g). = 
0.34 in 20% MeOH/CHCl3.  
$
%&0#//%34 2: δ 6.88 (s, 1H), 6.81 (d,  = 8.0 Hz, 1H), 6.76 (d, = 8.0 Hz, 1H), 3.80 (s, 3H), 
3.72 (s, 2H), 0.99 (s, 9H), 0.15 (s, 6H) ppm. 
$ 
&0$//%34 2: δ 150.9, 143.8, 136.5, 120.8, 
119.2, 111.1, 55.4, 46.0, 25.7, 18.4, *4.6 ppm.   
+0012"2"	$0,2:
Compound , was synthesized using the procedure described for compound by taking ) (2 g, 16.94 
mmol) in 90% yield (3.5 g). 0.36 in 10% EtOAC/Hexane. 
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$
%&0#//%34 2: δ 3.56 (q,  = 6.8 Hz,  = 15.2 Hz, 4H), 1.76 (bs, 1H), 1.50*1.58 (m, 4H), 1.33 
(t,  = 3.2 Hz, 4H) ppm. 
$ 
&0$//%34 2: δ 63.1, 62.8, 32.7, 32.7, 25.9, 25.6, 25.5, 18.3, *5.2 
ppm.   
$/0012"2	$0-2:
Compound - was synthesized using the procedure described for compound by taking + (5 g, 28.73 
mmol) in 90% yield (7.4 g). =0.47 in 10% EtOAC/Hexane. 
$
%&0)//%34 2: δ 3.56*3.61(m, 4H), 1.48*153(m, 4H), 1.26 (s, 12H), 0.87 (s, 9H), 0.02 (s, 6H) 
ppm. 
$ 
&0$)%34 2: δ 63.3, 62.9, 62.9, 32.8, 32.7, 29.5, 29.4, 25.9, 25.7, 25.7, 18.3 ppm.  
+0012"2"		0.2:
To a stirred solution of compound , (3 g, 12.93 mmol) in dry DCM (40 mL) pyridinium dichromate (3.5 g, 
9.56 mmol) at rt, followed by addition of acetic anhydride (43.96 mmol, 4.39  mL) at 0 
o
C, further stirring 
was continued at 50 
o
C for 5 h provided the compound . in 89% yield (2.85 g).  = 0.4 in 20% 
EtOAc/Hexane.  
$
%&0#//%34 2: δ 9.27 (bs, 1H), 3.59 (t,  = 12.8 Hz, 2H), 2.32 (t,  = 7.2 Hz, 2H), 2.07 (s, 
2H), 1.60*1.67 (m, 2H), 1.48*1.55 (m, 2H), 1.31*1.40 (m, 2H), 0.87 (s, 9H), 0.03 (s, 6H) ppm.  
$/0012"2		0$/2:
To a stirred solution of compound - (5 g, 19.23 mmol) in dry CH2Cl2 (60 mL) pyridinium dichromate (5.3 
g,14.23 mmol) at rt, followed by addition of acetic anhydride (65.38 mmol, 6.5 mL) at 0 
o
C, further stirring 
was continued at 50 
o
C  for 5 h provided the compound $/ in 85% yield (4.9 g).  = 0.34 in 30% 
EtOAc/Hexane.  
(&

(NEAT): νmax   2926, 2854, 1819, 1709, 1457, 1260, 1095 Cm
*1
.
 $
%&0#//%34 2: δ 3.57*
3.61 (m, 2H), 2.42*2.46 (m, 2H), 1.64 (t,  = 6.8 Hz, 2H), 1.49 (d,  = 12.8 Hz, 2H), 1.29 (s, 12H), 0.89 (s, 
9H), 0.04 (s, 6H) ppm. 
$ 
&0$//%34 2: δ 169.6, 63.3, 35.2, 32.8, 29.7, 29.3, 29.1, 28.8, 25.9, 
25.7, 24.2, 18.3, *5.2 ppm. %&0!(2 calcd for C16H34O3Si+Na 325.2175, found 325.2180.  
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+0012"20#0012"2 "132"		
0$$): 
To a stirred solution of compounds #(500 mg, 1.87 mmol)and .(506 mg, 2.05 mmol) in dry THF (8 mL) 
was added EDCI.HCl (442 mg, 2.24 mmol) and DMAP (251 mg, 2.05 mmol) at 0 
o
C, slowly it warmed to 
room temperature, stirring was continued for 12 h at room temperature until the completion of the 
reaction, after completion of the reaction, reaction mixture was diluted with ethyl acetate, the organic layer 
was washed with water, brine, dried over sodium sulphate, filter and evaporated  under reduced pressure 
gave crude compound which was further purified by using silica*gel column chromatography provided 
compound $$in 83% yield (780 mg).  = 0.4 in 30% EtOAc/Hexane. 
$
%&0#//%34 2: δ 6.75 (t,  = 8.4 Hz, 2H), 6.68 (d,  = 8.0 Hz, 1H), 6.03 (s, 1H), 4.32 (d,  = 
5.6 Hz, 2H), 3.76 (s, 3H), 3.62 (t,  = 5.6 Hz, 2H), 2.28 (t,  = 7.2 Hz, 2H), 1.83 (t,  = 6.8 Hz, 2H), 1.24 (s, 
2H), 0.97 (s, 9H), 0.85 (s, 9H), 0.12 (s, 6H), 0.00 (s, 6H) ppm. 
$ 
& 0$//%34 2: δ 172.7, 
151.0, 144.4, 131.8, 120.8, 120.1, 111.9, 62.2, 55.4, 43.4, 33.2, 29.7, 28.5, 25.9, 25.7, 18.4, 18.2, *4.6, *
5.3 ppm. 
$/0012"20#0012"2 "132		
0$2: 
To a stirred solution of compounds #(500 mg, 1.87 mmol)and $/(622 mg, 2.05 mmol) in dry THF (8 mL) 
was added EDCI.HCl (442 mg, 2.24 mmol) and DMAP (251 mg, 2.05 mmol) at 0 
o
C, slowly it warmed to 
room temperature, stirring was continued for 12 h at room temperature until the completion of the 
reaction, after completion of the reaction reaction mixture was diluted with ethyl acetate, the organic layer 
was washed with water, brine, dried over sodium sulphate, filter and evaporated  under reduced pressure 
gave crude compound which was further purified by using silica*gel column chromatography provided 
compound $in 85% yield (770 mg).  = 0.52 in 30% EtOAc/Hexane. 
$
%&0#//%34 2: δ 6.75*6.79 (m, 2H), 6.68 (t,  = 1.6 Hz, 1H), 5.72 (s, 1H), 4.33 (d,  = 5.6 Hz, 
2H), 3.77 (s, 3H), 3.56*3.59 (m, 2H), 2.17 (dd,  = 7.6 Hz, J = 12.4 Hz, 2H), 1.64 (bs, 2H), 1.49 (bs, 2H), 
1.25 (d,  = 8.8 Hz, 10H), 0.98 (s, 9H), 0.88 (s, 9H), 013 (s, 6H), 0.03 (s, 6H) ppm. 
$ 
&0$//%34
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 2: δ 172.9, 151.0, 144.4, 131.8, 120.8, 120.1, 111.8, 63.3, 55.4, 43.4, 36.8, 32.8, 29.7, 29.4, 29.3, 
29.3, 25.9, 25.8, 25.7, 18.4, 18.3, *4.6, *5.2  ppm.  
+"0#" "132"		0$ 2:
To a stirred solution of compound $$ (400 mg, 0.5472 mmol), in dry THF (10 mL) was added TBAF 1M in 
THF (0.87 mmol, 0.9 mL) at 0 
o
C, then stirring was continued for 4h at rt, after 4h quenched with 
saturated ammonium chloride solution, extracted with ethyl acetate, finally with brine, dried and 
evaporated provided the crude product which was purified by column chromatography gave the 
compound $  in 90% yield (210 mg).  = 0.2 in 100% EtOAc. 
$
%&0#//%34 2: δ 6.83 (d,  = 8.0 Hz, 1H), 6.78 (s, 1H), 6.72 (d,  = 8.0 Hz, 1H), 5.90 (s, 1H), 
4.31 (d,  = 5.6 Hz, 2H), 3.85 (s, 3H), 3.60 (t,  = 12.8 Hz, 2H), 2.18 (t,  = 7.6 Hz, 2H), 1.63*1.68 (m, 2H), 
1.52*1.59 (m, 3H), 1.36*1.42 (3H) ppm. 
$ 
&0$//%34 2: δ 172.9, 146.7, 145.1, 130.2, 120.7, 
114.4, 110.7, 62.4, 55.9, 43.5, 36.5, 32.2, 29.6, 29.3, 25.3, 25.2 ppm. %&0!(2 calcd for C14H21NO4+H 
268.1549, found 268.1543.  
$/"0#" "132		0$#2: 
To a stirred solution of compound $ (400 mg, 0.5472 mmol), in dry THF (10 mL) was added TBAF 1M in 
THF (0.87 mmol, 0.9 mL) at 0 
o
C, then stirring was continued for 4 h at rt, after 4h quenched with 
saturated ammonium chloride solution, extracted with ethyl acetate, finally with brine, dried and 
evaporated provided the crude product which was purified by column chromatography gave the 
compound $# in 90% yield (210 mg).  = 0.36 in 70% EtOAc/Hexane. 
$
%&0#//%34 2: δ 6.82 (d,  = 8.0 Hz, 1H), 6.78 (d,  = 1.6 Hz, 1H), 6.72 (dd,  = 1.6 Hz,  = 
8.0 Hz, 1H), 5.91 (s, 1H), 4.32 (d,  = 5.6 Hz, 2H), 3.85 (s, 3H), 3.59 (t,  = 6.4 Hz, 2H), 2.16 (t,  = 7.6 
Hz, 2H), 1.60 (t,  = 6.8 Hz, 2H), 1.51 (t,  = 7.2 Hz, 2H), 1.23 (s, 12H) ppm. 
$ 
&0$//%34 2: 
δ 173.1, 146.7, 145.1, 130.3, 120.7, 114.4, 110.7, 62.9, 55.9, 43.5, 36.7, 32.6, 29.6, 29.3, 29.2, 29.2, 
25.7, 25.6 ppm. %&0!(2 calcd for C18H29NO4+H 322.2175, found 324.2166.   
 
Page 32 of 69Journal of Pharmaceutical Sciences
9 
 
0#0012"2 "132+""		0$)2:
To a stirred solution of compound $$(700 mg, 1.41 mmol) in acetonitrile (15 mL) was added CeCl3.7H2O 
(1.0 g mg, 2.82 mmol) at room temperature, heated to reflux until completion of the reaction, after 
completion of the reaction, reaction mixture was partitioned between ethyl acetate and water, water layer 
was washed 2 times with ethyl acetate, the combined organic layer was washed with brine, dried over 
anhydrous sodium sulphate, filter and evaporation provided the crude product which was purified by 
silica*gel column chromatography gave the compound $) in 80% yield (430 mg).  = 0. 45 in 70% 
EOAc/Hexane. 
$
%&0#//%34 2: δ 6.75*6.78 (m, 2H), 6.68 (dd,  = 1.6 Hz,  = 8.0 Hz, 1H), 5.91 (s, 1H), 4.32 
(d,  = 5.6 Hz, 2H), 3.77 (s, 3H), 3.60 (t,  = 6.4 Hz, 2H), 2.19 (t,  = 7.2 Hz, 2H), 2.03 (s, 2H), 1.63*1.71 
(m, 2H), 1.52*1.58 (m, 2H), 1.35*1.45 (m, 2H), 1.25 (s, 2H), 0.98 (s, 9H), 0.13 (s, 6H) ppm. 
$ 
&0$//
%34 2: δ 172.8, 151.0, 144.4, 131.7, 120.8, 120.1, 111.9, 62.4, 55.5, 43.4, 36.5, 32.2, 29.6, 25.7, 
25.3, 25.3, 18.4, *4.6 ppm.  
0#0012"2 "132$/"		0$+2:
To a stirred solution of compound $(700 mg, 1.27 mmol) in acetonitrile (15 mL) was added CeCl3.7H2O 
(945 mg, 2.54 mmol) at room temperature, heated to reflux until completion of the reaction, after 
completion of the reaction, reaction mixture was partitioned between ethyl acetate and water, water layer 
was washed 2 times with ethyl acetate, the combined organic layer was washed with brine, dried over 
anhydrous sodium sulphate, filter and evaporation provided the crude product which was purified by 
silica*gel column chromatography gave the compound $+ in 81% yield (450 mg).  = 0. 35 in 60% 
EOAc/Hexane. 
$
%&0#//%34 2: δ 6.72 (d, = 8.4 Hz, 2H), 6.64 (d,  = 7.6 Hz, 1H), 4.28 (d,  = 5.6 Hz, 2H), 
3.73 (s, 3H), 3.52 (t,  = 6.4 Hz, 2H), 2.80 (bs, 1H), 2.13 (t,  = 7.6 Hz, 2H), 1.59 (bs, 2H), 1.47 (d,  = 6.4 
Hz, 2H), 1.22 (s, 12H), 0.95 (s, 9H), 0.10 (s, 6H) ppm. 
$ 
&0$//%34 2: δ 173.2, 150.9, 144.3, 
131.9, 120.7, 120.0, 111.8, 62.6, 55.4, 43.3, 36.6, 32.6, 29.4, 29.3, 29.2, 25.7, 18.4, *4.6 ppm.  
0#0012"2 "132+""		0$,2:
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To a stirred solution of compound $)(400 mg, 1.05 mmol) in dry CH2Cl2 (10 mL) was added pyridinium 
dichromate (293 mg, 0.78 mmol) followed by acetic anhydride (3.57 mmol, 357 KL) at 0 
o
C, then stirring 
was continued for 4 h at 50 
o
C, after 4h cooled to room temperature, evaporation of the solvent followed 
by column chromatography provided the compound $, in 83% yield (330 mg).  = 0.4 in 60% 
EtOAc/Hexane. 
$
%&0#//%34 2: δ 9.73 (t,  = 2.4 Hz, 1H), 6.76 (d,  = 6.4 Hz, 1H), 6.74 (d,  = 1.6 Hz, 1H), 
6.68 (dd,  = 1.6 Hz,  = 6.4 Hz, 1H), 5.88 (s, 1H), 4.32 (d,  = 4.4 Hz, 2H), 3.76 (s, 3H), 2.44 (dt,  = 1.2 
Hz,  = 5.6 Hz,  = 11.2 Hz, 2H), 2.19 (t, J = 5.6 Hz, 2H), 1.62*1.69 (m, 5H), 0.97 (s, 9H), 0.12 (s, 6H) 
ppm. 
$ 
&0$//%34 2: δ 202.1, 172.1, 151.0, 144.5, 131.7, 120.8, 120.2, 112.0, 55.5, 43.5, 
43.5, 36.2, 25.7, 25.0, 21.5, 18.4, *4.6 ppm.  
0#0012"2 "132$/"		0$-2:
To a stirred solution of compound $+ (400 mg, 0.91 mmol) in dry DCM (10 mL) was added pyridinium 
dichromate (253 mg, 0.67 mmol) followed by acetic anhydride (3.09 mmol, 310 KL) at 0 
o
C, then stirring 
was continued for 4 h at 50 
o
C, after 4h cooled to room temperature, evaporation of the solvent followed 
by column chromatography provided the compound $- in 80% yield (270 mg).  = 0.53 in 30% 
EtOAc/Hexane. 
$
%&0#//%34 2: δ 9.69 (s, 1H), 6.72 (d,  = 8.0 Hz, 2H), 6.64 (d,  = 8.0 Hz, 1H), 6.03 (s, 1H), 
4.28 (d,  = 5.6 Hz, 2H), 3.73 (s, 3H), 2.34 (t,  = 7.2 Hz, 2H), 2.13 (t,  = 7.2 Hz, 2H), 1.56 (t,  = 6.4 Hz, 
4H), 1.25 (s, 9H), 0.94 (s, 9H), 0.10 (s, 6H) ppm. 
$ 
& 0$//%34 2: δ 202.9, 172.9, 150.9, 
144.3, 131.9, 120.7, 120.0, 111.8, 55.4, 43.8, 43.3, 36.6, 29.1, 29.1, 29.0, 25.6, 21.9, 18.4, *4.6 ppm.  
0#0012"2 "132+""		0$.2:
To a stirred solution of compound $, (200 mg, 0.52 mmol), in dry THF (6 mL) was added TBAF 1M in 
THF (0.63 mmol, 0.63 mL) at 0 
o
C, then stirring was continued for 3 h at rt, after 3 h quenched with 
saturated ammonium chloride solution, extracted with ethyl acetate, finally with brine, dried and 
evaporated provided the crude product which was purified by column chromatography gave the 
compound $. in 90% yield (125 mg).  = 0.38 in 100% EtOAc.     
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$
%&0#//%34 2: δ 9.75 (s, 1H), 6.84 (d,  = 8.0 Hz, 1H), 6.80 (s, 1H), 6.75 (d,  = 8.4 Hz, 1H), 
5.80 (t,  = 3.6 Hz, 1H), 4.34 (d,  = 5.6 Hz, 2H), 3.87 (s, 3H), 2.46 (t,  = 6.8 Hz, 2H), 2.20 (t,  = 6.8 Hz, 
2H), 1.66 (t,  = 2.8 Hz, 5H) ppm. 
$ 
& 0$//%34  2: δ 202.2, 172.2, 146.7, 145.1, 130.1, 
120.8, 114.4, 110.7, 55.9, 43.6, 36.3, 29.6, 25.0, 21.5 ppm. %& 0!(2 calcd for C14H19NO4+H 
266.1392, found 266.1384.   
0#" "132$/"		0/2:
To a stirred solution of compound $- (200 mg, 0.54 mmol), in dry THF (6 mL) was added TBAF 1M in 
THF (0.65 mmol, 0.65 mL) at 0 
o
C, then stirring was continued for 3 h at rt, after 3h quenched with 
saturated ammonium chloride solution, extracted with ethyl acetate, finally with brine, dried and 
evaporated provided the crude product which was purified by column chromatography gave the 
compound / in 90% yield (160 mg).  = 0.36 in 60% EtOAc/Hexane. 
$
%&0#//%34 2: δ 9.75 (s, 1H), 6.85 (d,  = 8.0 Hz, 1H), 6.80 (s, 1H), 6.75 (d,  = 8.0 Hz, 1H), 
5.70 (s, 1H), 4.34 (d,  = 5.6 Hz, 2H), 3.87 (s, 3H), 2.39 (t,  = 7.2 Hz, 2H), 2.17 (t, = 7.6 Hz, 2H), 1.61 
(t,  = 6.4 Hz, 5H), 1.29 (s, 8H) ppm. 
$ 
&0$//%34 2: δ 203.0, 173.0, 146.8, 145.1, 130.2, 
120.6, 114.4, 110.7, 55.8, 43.8, 43.4, 36.7, 29.6, 29.1, 29.0, 25.7, 21.9 ppm. %& 0!(2 calcd for 
C18H27NO4+H 322.2018, found 322.22010.

	

 !""##
$

%#&	%'($)*+,)-
./012.)).#3
#404%
05,
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
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PCR products in a 1% w/v agarose gel. While the bands for β*actin and TRPV4 are visible a 
band for TRPV1 was not observed. 
 
Total RNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany), following the 
manufacturer’s protocol. The cDNAs were synthesized with the reverse transcription system 
(Promega, Madison, USA) from 1 Kg of total RNA per sample by following the manufacturer’s 
instructions. The PCR primer sets were designed as follows: TRPV1 canis Forward: 5’* 
CCCCTGGATGGAGACCCTAA *3’ and Reverse, 5’* ATGGCAATATGCAGGGCTG *3’; TRPV4 
canis Forward, 5’* GATCGGGGTCTTTCAGCACA *3’ and Reverse, 5’* 
TCCCGCAGCAGTTCATTGAT *3’; β*actin canis Forward, 5’* CAAAGCCAACCGTGAGAAG *3’ 
and Reverse, 5’* CAGAGTCCATGACAATACCAG *3’. The primer sets were purchased from 
Eurofins MWG Operon (Ebersberg, Germany). Amplification was performed using a 
Thermocycler of the type C1000 (Bio*Rad Laboratories GmbH, Munich, Germany). Cycling 
conditions were 95°C for 2 min, and then 40 cycles at 95°C for 15 s and 60°C for 1 min. The 
PCR products were ran for 40 minutes in a 1% w/v agarose gel. A DNA ladder was also 
included (GeneRuler™ DNA Ladder Mix, Thermo Fisher Scientific, Waltham, USA). 
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